Pfizer seeks $1.5B adult market for Prevnar 13

Pfizer has high hopes for Prevnar-13, the vaccine it acquired in its buyout of Wyeth. An FDA panel has already voted in favor of the updated vaccine, and the company is awaiting final approval of the shot for infants and children.

But Martin Mackay, president of of PharmaTherapeutics at Pfizer, predicts that the company's plans for Prevnar-13 won't end there. The pharma giant plans to ask the FDA this year to approve the vaccine for adults older than 50. Approval for that population alone could account for $1.5 billion in sales, and Prevnar-13's annual sales could peak at a whopping $4.5 billion.

- check out the Reuters article

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.